As of January 2021, SARS-CoV-2 has killed over 2 million individuals across the world . As such, there is an urgent need for vaccines and therapeutics to reduce the burden of COVID-19 . Several vaccines, including mRNA, vector-based vaccines, and inactivated vaccines, have been approved for emergency use in various countries . However, the slow roll-out of vaccines and insufficient global supply remains a challenge to turn the tide of the pandemic . Moreover, vaccines are important tools for preventing the disease but therapeutic tools to treat patients are also needed . As such, since the beginning of the pandemic, repurposed FDA-approved drugs have been sought as potential therapeutic options for COVID-19 due to their known safety profiles and potential anti-viral effects . One of these drugs is ivermectin (IVM), an antiparasitic drug created in the 1970s . IVM later exerted antiviral activity against various viruses including SARS-CoV-2 . In this review, we delineate the story of how this antiparasitic drug was eventually identified as a potential treatment option for COVID-19 . We review SARS-CoV-2 lifecycle, the role of the nucleocapsid protein, the turning points in past research that provided initial 'hints' for IVM's antiviral activity and its molecular mechanism of action- and finally, we culminate with the current clinical findings.